Rudkowski Z, Latos T
Padiatr Padol. 1980;15(4):351-64.
This study should demonstrate the efficiency of a new bronchosecretolytic substance, Eprazinone, in therapy of acute and chronic bronchitis with children. The following groups of children have been treated: 1) 10 children with acute bronchitis (aged 5-14 years); 2) 12 children with chronic bronchitis (aged 7-14 years). To objectivize the effect of the substance, exact laboratory- and check-up examinations have been done daily. The dose was 3 x 1 tablet/day for school children, for younger children 2 x 1 suppository daily. All children have been treated over 5-8 days. The results of the therapy with Eprazinone in both groups show that -Eprazinone is an efficient remedy to cure symptomatically chronic and acute bronchitis in children. It shows an excellent mucolytic activity.
本研究旨在证明一种新型支气管分泌物溶解剂——依普拉酮治疗儿童急慢性支气管炎的疗效。对以下几组儿童进行了治疗:1)10名急性支气管炎儿童(5至14岁);2)12名慢性支气管炎儿童(7至14岁)。为客观评估该药物的疗效,每天都进行了精确的实验室检查和体检。学龄儿童的剂量为每日3次,每次1片;年幼儿童的剂量为每日2次,每次1粒栓剂。所有儿童均接受了5至8天的治疗。两组使用依普拉酮治疗的结果表明,依普拉酮是一种有效对症治疗儿童急慢性支气管炎的药物。它具有出色的黏液溶解活性。